Bio-Rad Laboratories, Inc. (BIO)

NYSE: BIO · IEX Real-Time Price · USD
467.46
+3.20 (0.69%)
Jan 31, 2023, 4:04 PM EST - Market closed
0.69%
Market Cap 13.67B
Revenue (ttm) 2.80B
Net Income (ttm) -6.03B
Shares Out 29.24M
EPS (ttm) -201.41
PE Ratio n/a
Forward PE 28.01
Dividend n/a
Ex-Dividend Date n/a
Volume 167,195
Open 466.43
Previous Close 464.26
Day's Range 456.67 - 470.92
52-Week Range 344.63 - 670.62
Beta 0.90
Analysts Buy
Price Target 602.82 (+28.96%)
Earnings Date Feb 16, 2023

About BIO

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics,... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 1952
Employees 8,200
Stock Exchange NYSE
Ticker Symbol BIO
Full Company Profile

Financial Performance

In 2021, BIO's revenue was $2.92 billion, an increase of 14.81% compared to the previous year's $2.55 billion. Earnings were $4.25 billion, an increase of 11.55%.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for BIO stock is "Buy." The 12-month stock price forecast is $602.82, which is an increase of 28.96% from the latest price.

Price Target
$602.82
(28.96% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Bio-Rad to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for t...

3 weeks ago - Business Wire

Here's Why You Should Retain Bio-Rad (BIO) Stock for Now

Investors are optimistic about Bio-Rad (BIO), led by robust demand in the Life Science and Clinical Diagnostics arms.

3 weeks ago - Zacks Investment Research

Bio-Rad to Present Company Overview at J.P. Morgan 41st Annual Healthcare Conference

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that Norman Schwartz, P...

3 weeks ago - Business Wire

Bio-Rad (BIO) Core Diagnostic Sales Grow Amid Supply Challenges

Bio-Rad's (BIO) underlying Life Science currency-neutral core revenue growth is primarily driven by Western loading, qPCR, process media and antibody products sales.

1 month ago - Zacks Investment Research

The Bunny Portfolio Has Averaged 13.6% Per Year

What do you call a stock that has a great earnings growth history, yet sells for modest price?

Other symbols: AELBCSFBSIGCCSCGCMC
1 month ago - GuruFocus

Bio-Rad (BIO) Q3 Earnings Surpass Estimates, Margins Down

Bio-Rad's (BIO) third-quarter revenues decline mainly as a result of lower COVID-related sales compared with the year-ago period.

3 months ago - Zacks Investment Research

Bio-Rad Laboratories (BIO) Surpasses Q3 Earnings Estimates

Bio-Rad (BIO) delivered earnings and revenue surprises of 0.39% and 1.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Bio-Rad Reports Third-Quarter 2022 Financial Results

HERCULES, Calif.

3 months ago - Business Wire

Should You Buy Bio-Rad Laboratories Stock After Its 50% Fall This Year?

Bio-Rad Laboratories stock (NYSE: BIO), a life science research and clinical diagnostic products company, has seen a 48% fall this year, significantly underperforming the broader S&P500 index, down 24...

Other symbols: RAD
4 months ago - Forbes

Bio-Rad and German-based biotech Qiagen weighing latest tie-up in medical-diagnostic market

Bio-Rad Laboratories Inc. is in talks to combine with fellow life-sciences company Qiagen NV in a deal that would be worth more than $10 billion, according to people familiar with the matter.

Other symbols: QGEN
4 months ago - Market Watch

Diagnostics firm Bio-Rad in talks to merge with Qiagen - WSJ

California-based diagnostics company Bio-Rad Laboratories is in talks to merge with Qiagen NV , the Wall Street Journal reported on Monday, citing people familiar with the matter.

Other symbols: QGEN
4 months ago - Reuters

Bio-Rad Laboratories in Talks to Combine With Qiagen

Bio-Rad Laboratories Inc. is in talks to combine with fellow life-sciences company Qiagen NV in a deal that would be worth more than $10 billion, according to people familiar with the matter.

Other symbols: QGEN
4 months ago - WSJ

Here's Why You Should Invest in Bio-Rad (BIO) Stock Now

Investors are optimistic about Bio-Rad's (BIO) better-than-expected results and continued growth across major geographies.

5 months ago - Zacks Investment Research

4 Stocks to Watch Amid Recovering Medical Products Industry

Despite the COVID-induced challenges, rising demand for IVD coupled with dependence on AI & Robotics should lend support to the Zacks Medical-Products industry. ZBH, BIO, LNTH and HAE are well-poised ...

Other symbols: HAELNTHZBH
5 months ago - Zacks Investment Research

Bio-Rad Acquires Curiosity Diagnostics

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, announced today that it has reached an ag...

6 months ago - Business Wire

Bio-Rad (BIO) Q2 Earnings Surpass Estimates, Gross Margin Up

Overall demand for Bio-Rad's (BIO) Life Science and Clinical Diagnostics continues to be strong on localized surges of COVID-19.

6 months ago - Zacks Investment Research

Bio-Rad Laboratories (BIO) Surpasses Q2 Earnings and Revenue Estimates

Bio-Rad (BIO) delivered earnings and revenue surprises of 37.40% and 3.94%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Bio-Rad Reports Second-Quarter 2022 Financial Results

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the...

6 months ago - Business Wire

Bio-Rad to Report Second Quarter 2022 Financial Results on Thursday, July 28, 2022

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for the...

7 months ago - Business Wire

Bio-Rad Publishes Corporate Sustainability Report

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today released its inaugural corporate su...

7 months ago - Business Wire

Bio-Rad (BIO) Immunohematology Arm Recovers, New Launches Aid

Bio-Rad's (BIO) qPCR business is experiencing excellent uptake from the new-generation CFX Opus platform.

8 months ago - Zacks Investment Research

Wall Street Analysts Believe Bio-Rad (BIO) Could Rally 53%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 52.9% in Bio-Rad (BIO). While the effectiveness of this highly sought-after metric is questionable, the positiv...

8 months ago - Zacks Investment Research

Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Up

Bio-Rad's (BIO) first-quarter 2022 revenues decline year over year due to lower COVID-related demand.

9 months ago - Zacks Investment Research